Management of Refractory Acute Agitation

Pharmacological Interventions

The National Comprehensive Cancer Network (NCCN) recommends continuing haloperidol at 0.5-2mg every 1 hour as needed until the agitation episode is under control 1, 2
For patients with persistent acute agitation after receiving initial pharmacotherapy, the NCCN guidelines suggest adding lorazepam 0.5-2mg every 4-6 hours if agitation remains refractory to high doses of neuroleptics 1, 2, 3
The combination approach of neuroleptic and benzodiazepine is specifically recommended for refractory agitation, as the presence of therapeutic neuroleptic levels prevents paradoxical excitation sometimes seen when delirious/agitated patients receive lorazepam alone 1, 2, 3

The NCCN guidelines recommend obtaining or reviewing baseline ECG given the combination of haloperidol and olanzapine, both of which prolong QT interval 4
Haloperidol causes mean QT prolongation of 7ms at usual doses and carries moderate cardiac risk, and patients should be monitored for electrolyte abnormalities, bradycardia, or other QT-prolonging medications 4
Patients receiving haloperidol should be monitored for acute dystonia, akathisia, and Parkinsonian symptoms, which occur in approximately 20% of patients 5, 4

If the current regimen fails, consider changing to intramuscular administration, as IM haloperidol or IM olanzapine may provide more rapid and reliable absorption 2, 3
Alternative antipsychotic options include chlorpromazine ± lorazepam for refractory cases, although chlorpromazine should only be used IV in bed-bound patients due to hypotensive effects 2, 3, 6

While managing acute agitation pharmacologically, simultaneously evaluate for reversible medical causes, such as hypoxia, metabolic derangements, infection, CNS events, urinary retention, and bowel obstruction 1, 2
Medication-induced causes, such as anticholinergics, steroids, opioid neurotoxicity, benzodiazepine or alcohol withdrawal, should also be assessed 1, 2, 6
Substance intoxication, particularly anticholinergic or sympathomimetic agents, which may be exacerbated by antipsychotics, should be considered 5